T. Rowe Price Associates’s Relay Therapeutics RLAY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19.2M Buy
1,924,938
+279,535
+17% +$2.5M ﹤0.01% 1050
2025
Q4
$13.9M Buy
1,645,403
+507,722
+45% +$3.62M ﹤0.01% 1157
2025
Q3
$5.94M Sell
1,137,681
-1,738,255
-60% -$6.63M ﹤0.01% 1350
2025
Q2
$9.95M Sell
2,875,936
-601,855
-17% -$1.79M ﹤0.01% 1115
2025
Q1
$9.11M Buy
3,477,791
+156,050
+5% +$611K ﹤0.01% 1132
2024
Q4
$13.7M Sell
3,321,741
-1,958,550
-37% -$10.7M ﹤0.01% 1076
2024
Q3
$37.4M Buy
5,280,291
+241,276
+5% +$1.8M ﹤0.01% 831
2024
Q2
$32.9M Sell
5,039,015
-1,840,582
-27% -$12.6M ﹤0.01% 836
2024
Q1
$57.1M Sell
6,879,597
-1,701,570
-20% -$16.6M 0.01% 694
2023
Q4
$94.5M Sell
8,581,167
-27,779
-0.3% -$234K 0.01% 561
2023
Q3
$72.4M Buy
8,608,946
+263,429
+3% +$2.83M 0.01% 577
2023
Q2
$105M Buy
8,345,517
+1,482,557
+22% +$18.4M 0.01% 515
2023
Q1
$113M Buy
6,862,960
+2,369,956
+53% +$42.5M 0.02% 487
2022
Q4
$67.1M Sell
4,493,004
-68,359
-1% -$1.31M 0.01% 584
2022
Q3
$102M Sell
4,561,363
-738,944
-14% -$16.2M 0.02% 485
2022
Q2
$88.8M Buy
5,300,307
+300,589
+6% +$6.44M 0.01% 698
2022
Q1
$150M Buy
4,999,718
+844,377
+20% +$20.5M 0.02% 615
2021
Q4
$128M Buy
4,155,341
+2,537,388
+157% +$80.2M 0.01% 694
2021
Q3
$51M Buy
1,617,953
+444,471
+38% +$15M ﹤0.01% 1003
2021
Q2
$42.9M Sell
1,173,482
-331,610
-22% -$10.9M ﹤0.01% 1082
2021
Q1
$52M Buy
1,505,092
+731,517
+95% +$31.7M 0.01% 989
2020
Q4
$32.1M Sell
773,575
-13,927
-2% -$630K ﹤0.01% 1092
2020
Q3
$33.5M Buy
+787,502
New +$30M ﹤0.01% 1002

Other funds holding RLAY